Olema Pharmaceuticals (OLMA) Competitors

Olema Pharmaceuticals logo
$7.36 -0.20 (-2.65%)
Closing price 04:00 PM Eastern
Extended Trading
$7.36 +0.00 (+0.07%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OLMA vs. BEAM, CLDX, PVLA, SEPN, and RCUS

Should you buy Olema Pharmaceuticals stock or one of its competitors? Olema Pharmaceuticals's main competitors and comparable companies include Beam Therapeutics (BEAM), Celldex Therapeutics (CLDX), Palvella Therapeutics (PVLA), Septerna (SEPN), and Arcus Biosciences (RCUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Olema Pharmaceuticals compare to Beam Therapeutics?

Olema Pharmaceuticals (NASDAQ:OLMA) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Beam Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Beam Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/A-$162.45M-$2.36N/A
Beam Therapeutics$146.64M16.14-$79.99M-$1.04N/A

Olema Pharmaceuticals has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

Olema Pharmaceuticals has a net margin of 0.00% compared to Beam Therapeutics' net margin of -73.04%. Beam Therapeutics' return on equity of -32.76% beat Olema Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Olema PharmaceuticalsN/A -53.67% -47.39%
Beam Therapeutics -73.04%-32.76%-25.80%

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Beam Therapeutics had 13 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 24 mentions for Beam Therapeutics and 11 mentions for Olema Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.73 beat Olema Pharmaceuticals' score of 0.19 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Olema Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Beam Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Olema Pharmaceuticals presently has a consensus price target of $40.60, indicating a potential upside of 437.04%. Beam Therapeutics has a consensus price target of $47.64, indicating a potential upside of 108.35%. Given Olema Pharmaceuticals' higher possible upside, equities analysts plainly believe Olema Pharmaceuticals is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Olema Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77

Summary

Beam Therapeutics beats Olema Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

91.8% of Olema Pharmaceuticals shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Celldex Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market.

In the previous week, Celldex Therapeutics had 4 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 15 mentions for Celldex Therapeutics and 11 mentions for Olema Pharmaceuticals. Celldex Therapeutics' average media sentiment score of 0.92 beat Olema Pharmaceuticals' score of 0.19 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celldex Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Olema Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Celldex Therapeutics presently has a consensus target price of $64.08, indicating a potential upside of 122.28%. Olema Pharmaceuticals has a consensus target price of $40.60, indicating a potential upside of 437.04%. Given Olema Pharmaceuticals' higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
Olema Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Olema Pharmaceuticals has lower revenue, but higher earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$158K14,335.08-$258.76M-$4.30N/A
Olema PharmaceuticalsN/AN/A-$162.45M-$2.36N/A

Celldex Therapeutics' return on equity of -52.66% beat Olema Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex TherapeuticsN/A -52.66% -47.58%
Olema Pharmaceuticals N/A -53.67%-47.39%

Summary

Olema Pharmaceuticals beats Celldex Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Palvella Therapeutics?

Olema Pharmaceuticals (NASDAQ:OLMA) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Olema Pharmaceuticals currently has a consensus price target of $40.60, indicating a potential upside of 437.04%. Palvella Therapeutics has a consensus price target of $213.85, indicating a potential upside of 40.25%. Given Olema Pharmaceuticals' higher probable upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Olema Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.00

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Palvella Therapeutics' return on equity of -44.44% beat Olema Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Olema PharmaceuticalsN/A -53.67% -47.39%
Palvella Therapeutics N/A -44.44%-36.75%

Olema Pharmaceuticals has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market.

In the previous week, Palvella Therapeutics had 13 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 24 mentions for Palvella Therapeutics and 11 mentions for Olema Pharmaceuticals. Palvella Therapeutics' average media sentiment score of 0.97 beat Olema Pharmaceuticals' score of 0.19 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Olema Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Palvella Therapeutics
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Palvella Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Olema PharmaceuticalsN/AN/A-$162.45M-$2.36N/A
Palvella Therapeutics$42.81M52.07-$41.72M-$5.50N/A

Summary

Palvella Therapeutics beats Olema Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Septerna?

Septerna (NASDAQ:SEPN) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Septerna has higher revenue and earnings than Olema Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$96.27M21.04-$48.88M-$1.29N/A
Olema PharmaceuticalsN/AN/A-$162.45M-$2.36N/A

Septerna has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market.

Septerna currently has a consensus target price of $56.44, indicating a potential upside of 32.50%. Olema Pharmaceuticals has a consensus target price of $40.60, indicating a potential upside of 437.04%. Given Olema Pharmaceuticals' higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Olema Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Olema Pharmaceuticals has a net margin of 0.00% compared to Septerna's net margin of -61.29%. Septerna's return on equity of -14.98% beat Olema Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Septerna-61.29% -14.98% -10.03%
Olema Pharmaceuticals N/A -53.67%-47.39%

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Septerna had 16 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 27 mentions for Septerna and 11 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.19 beat Septerna's score of 0.11 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Septerna
4 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Olema Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Septerna beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arcus Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Olema Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -453.00%. Olema Pharmaceuticals' return on equity of -53.67% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcus Biosciences-453.00% -91.65% -46.72%
Olema Pharmaceuticals N/A -53.67%-47.39%

In the previous week, Olema Pharmaceuticals had 9 more articles in the media than Arcus Biosciences. MarketBeat recorded 11 mentions for Olema Pharmaceuticals and 2 mentions for Arcus Biosciences. Olema Pharmaceuticals' average media sentiment score of 0.19 beat Arcus Biosciences' score of 0.15 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcus Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Olema Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arcus Biosciences currently has a consensus price target of $39.36, indicating a potential upside of 125.58%. Olema Pharmaceuticals has a consensus price target of $40.60, indicating a potential upside of 437.04%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Arcus Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
Olema Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Olema Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$247M10.17-$353M-$3.63N/A
Olema PharmaceuticalsN/AN/A-$162.45M-$2.36N/A

Summary

Olema Pharmaceuticals beats Arcus Biosciences on 11 of the 15 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OLMA vs. The Competition

MetricOlema PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$644.78M$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-3.1224.2434.3430.11
Price / SalesN/A14.858.005.33
Price / CashN/A21.8921.0222.34
Price / Book1.254.354.763.85
Net Income-$162.45M-$24.19M$3.52B$393.14M
7 Day PerformanceN/A-7.26%-5.34%-4.53%
1 Month Performance11.85%-4.96%-3.61%-5.86%
1 Year Performance-12.38%-2.87%0.01%-7.78%

Olema Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OLMA
Olema Pharmaceuticals
1.7626 of 5 stars
$7.36
-2.6%
$40.60
+451.6%
-10.0%$644.78MN/AN/A150
BEAM
Beam Therapeutics
2.7368 of 5 stars
$24.53
-9.2%
$47.36
+93.1%
+5.3%$2.54B$139.74MN/A540
CLDX
Celldex Therapeutics
2.0827 of 5 stars
$31.03
-0.7%
$64.08
+106.5%
+12.8%$2.44B$1.54MN/A198
PVLA
Palvella Therapeutics
2.6388 of 5 stars
$165.94
-4.7%
$213.85
+28.9%
+82.1%$2.39B$42.81MN/A29
SEPN
Septerna
2.2612 of 5 stars
$51.00
+0.5%
$56.44
+10.7%
+83.1%$2.38B$45.95MN/A130

Related Companies and Tools


This page (NASDAQ:OLMA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners